Oppenheimer analyst Justin Kim raised the firm’s price target on Alpine Immune Sciences (ALPN) to $33 from $30 and keeps an Outperform rating on the shares. The firm has increased conviction in BAFF/APRIL targeting therapies, including povetacicept, and their potential to redefine the IgAN treatment paradigm following Phase 2b data from Vera (VERA), the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALPN:
- 3 Best Stocks to Buy Now, 12/25/2023, According to Top Analysts
- Alpine Immune Sciences price target raised to $32 from $17 at H.C. Wainwright
- Alpine Immune amends acazicolcept option and license agreement with AbbVie
- Oppenheimer, Wedbush say buy these biotech stocks for 2024
- Alpine Immune Sciences named a best idea for 2024 at TD Cowen
